# Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

> **NCT00389935** · PHASE2 · COMPLETED · sponsor: **Northport Veterans Affairs Medical Center** · enrollment: 14 (actual)

## Conditions studied

- Arteriovenous Malformation
- Hereditary Hemorrhagic Telangiectasia
- Hematochezia
- Melena

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00389935
- **Lead sponsor:** Northport Veterans Affairs Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2011-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389935, "Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00389935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*